Alder Biopharmaceuticals to present new data on eptinezumab at AHS meeting
Alder BioPharmaceuticals announced that it will present new analyses of efficacy and quality of life data from its clinical trials for eptinezumab at the American Headache Society's 61st Annual Scientific Meeting in Philadelphia, PA being held on July 11-14, 2019. Eptinezumab is an investigational monoclonal antibody delivered by IV administration. It was designed for 100% bioavailability with high specificity and strong binding for rapid, robust and sustained suppression of calcitonin gene-related peptide. At the meeting, more than a dozen presentations related to eptinezumab's safety and efficacy of response in migraine prevention will be shared, including an analysis of 100% response rates for patients with episodic or chronic migraine who were treated with eptinezumab in the Phase 3 PROMISE-1 and PROMISE-2 clinical trials. Another key presentation will focus on the impact of eptinezumab on migraine severity and quality of life. Additional eptinezumab presentations at the meeting will feature a visual representation of the molecule's binding properties and further analyses related to safety and quality of life data. The U.S. Food and Drug Administration accepted the Biologics License Application (BLA) filing for eptinezumab in April 2019, and set a Prescription Drug User Fee Act target action date of February 21, 2020. If approved, eptinezumab will be the first-to-market IV therapy for migraine prevention.